-
公开(公告)号：US12071454B2
公开(公告)日：2024-08-27
申请号：US17061065
申请日：2020-10-01
申请人： Sanofi
发明人： Gary J. Nabel , Chih-Jen Wei , Kurt Swanson , Pradeep Dhal , Ram Dharanipragada , Magnus Besev
IPC分类号： C07K14/195
CPC分类号： C07K14/195 , C07K2319/30
摘要： Antigenic respiratory syncytial virus (RSV) polypeptides for use in eliciting antibodies against RSV are provided. Also provided are antigenic polypeptides comprising an RSV polypeptide and a ferritin protein.
-
公开(公告)号：US20240207033A1
公开(公告)日：2024-06-27
申请号：US18288096
申请日：2022-04-25
申请人： Sanofi
发明人： Lionel Vedrine , Christina Laskar , Pradeep Dhal , Craig Harvey Nelson , Mark Robson Humphries , Carys Eleri Lee , Nicholas Oliver Harding
CPC分类号： A61F2/022 , A61K35/39 , A61K38/18 , A61F2210/0076 , A61F2230/0091 , A61F2240/001 , A61F2250/0023
摘要： A method of manufacturing a therapeutic device includes providing a member that defines first pores having a first average size that (i) allows passage of a therapeutic agent through the first pores and (ii) prevents passage of immune cells through the first pores. The method further includes spinning the member about an axis of the member and applying a fibrous material to the member while the member spins to form a coating that surrounds the member. The coating defines second pores having a second average size that is larger than the first average size, and the second pores are sized to promote vascularization along the coating. The member and the coating together form a container of the therapeutic device, and the container defines an interior region for accommodating a plurality of cells capable of producing the therapeutic agent.
-
公开(公告)号：US20210017237A1
公开(公告)日：2021-01-21
申请号：US17061065
申请日：2020-10-01
申请人： Sanofi
发明人： Gary J. Nabel , Chih-Jen Wei , Kurt Swanson , Pradeep Dhal , Ram Dharanipragada , Magnus Besev
IPC分类号： C07K14/195
摘要： This disclosure relates to antigenic respiratory syncytial virus (RSV) polypeptides for use in eliciting antibodies against RSV. Also disclosed are antigenic polypeptides comprising an RSV polypeptide and a ferritin protein.
-
4.发明申请公开(公告)号：US20200023070A1
公开(公告)日：2020-01-23
申请号：US16426926
申请日：2019-05-30
申请人： SANOFI
发明人： Dieter Kadereit , Thomas Olpp , Michael Walden , Nils Poth , Mandy Mohnicke , Michael Wagner , Pradeep Dhal
摘要： The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon/GIP triple receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-Y-R2 groups, wherein Y represents an GLP-1/Glucagon/GIP triple receptor agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon/GIP triple receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said conjugates as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon/GIP triple receptor agonist.
-
5.发明公开公开(公告)号：US20240207588A1
公开(公告)日：2024-06-27
申请号：US18288099
申请日：2022-04-25
申请人： SANOFI
发明人： Lionel Vedrine , Christina Laskar , Pradeep Dhal , Craig Harvey Nelson , Mark Robson Humphries , Carys Eleri Lee , Nicholas Oliver Harding
CPC分类号： A61M37/0015 , A61F2/022 , A61M2037/0023 , A61M2207/10
摘要： A method of manufacturing a therapeutic device includes forming a container wall that is sized to contain multiple cells capable of producing a therapeutic agent within an interior region of the container wall. The method further includes exposing the container wall to a solvent to remove material from the container wall to define first pores along an interior portion of the container wall and second pores along an exterior portion of the container wall. The first pores have a first average size that (i) allows passage of the therapeutic agent through the first pores and (ii) prevents passage of immune cells through the first pores. The second pores have a second average size that is larger than the first average size, and the second pores are sized to promote vascularization along the exterior portion.
-
公开(公告)号：US20240197959A1
公开(公告)日：2024-06-20
申请号：US18288092
申请日：2022-04-25
申请人： Sanofi
发明人： Lionel Vedrine , Christina Laskar , Pradeep Dhal , Craig Harvey Nelson , Mark Robson Humphries , Carys Eleri Lee , Nicholas Oliver Harding
CPC分类号： A61L27/3895 , A61K38/1825 , A61K38/1841 , A61K38/1858 , A61K38/1866 , A61K38/28 , A61L27/227 , A61L27/34 , A61L27/3804 , A61L27/56 , A61L2300/11 , A61L2300/414 , A61L2300/43
摘要： An implantable device for providing a therapeutic agent includes a container configured to contain multiple cells capable of producing the therapeutic agent within an interior region of the container and a substance capable of reacting to generate oxygen for the multiple cells within the interior region of the container. The container defines first pores defined by an interior wall portion of the container and second pores defined by an exterior wall portion of the container. The first pores have a first average size that (i) allows passage of the therapeutic agent through the first pores and (ii) prevents passage of immune cells through the first pores. The second pores have a second average size that is larger than the first average size, and the second pores are sized to promote vascularization along the exterior wall portion.
-
公开(公告)号：US20240197464A1
公开(公告)日：2024-06-20
申请号：US18288087
申请日：2022-04-25
申请人： Sanofi
发明人： Lionel Vedrine , Christina Laskar , Pradeep Dhal , Craig Harvey Nelson , Mark Robson Humphries , Carys Eleri Lee , Nicholas Oliver Harding
CPC分类号： A61F2/022 , A61L27/3804 , A61L27/54 , A61L27/56 , A61F2230/0069 , A61L2300/414
摘要： An implantable device for providing a therapeutic agent includes a container configured to contain multiple cells capable of producing the therapeutic agent within an interior region of the container. The container defines first pores defined by an interior wall portion of the container and second pores defined by an exterior wall portion of the container. The first pores have a first average size that (i) allows passage of the therapeutic agent and oxygen through the first pores and (ii) prevents passage of immune cells through the first pores. The second pores have a second average size that is larger than the first average size, and the second pores are sized to promote vascularization and oxygen transfer along the exterior wall portion.
-
公开(公告)号：US10806797B2
公开(公告)日：2020-10-20
申请号：US15574480
申请日：2016-06-02
申请人： SANOFI
发明人： Dieter Kadereit , Michael Wagner , Thomas Olpp , Nino Meyer , Pradeep Dhal , Paul Konowicz , Robert Miller , James Stefano , Magnus Besev , Martin Bossart , Katrin Lorenz , Torsten Haack , Andreas Evers
摘要： The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon agonist linker conjugate Z-L1-L2-L-Y—R20, wherein Y represents an GLP-1/Glucagon agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon agonist.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.016 秒)
